Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Non Operating Income (2022 - 2026)

TriSalus Life Sciences has reported Non Operating Income over the past 5 years, most recently at -$76000.0 for Q1 2026.

  • For Q1 2026, Non Operating Income rose 69.72% year-over-year to -$76000.0; the TTM value through Mar 2026 reached -$281000.0, up 31.46%, while the annual FY2025 figure was -$456000.0, 46.15% down from the prior year.
  • Non Operating Income for Q1 2026 was -$76000.0 at TriSalus Life Sciences, down from -$71000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $3.5 million in Q1 2022 and troughed at -$349000.0 in Q4 2022.
  • A 5-year average of $270955.6 and a median of -$44000.0 in 2024 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: plummeted 705.26% in 2024 and later skyrocketed 69.72% in 2026.
  • Year by year, Non Operating Income stood at -$349000.0 in 2022, then grew by 7.74% to -$322000.0 in 2023, then surged by 68.32% to -$102000.0 in 2024, then surged by 30.39% to -$71000.0 in 2025, then decreased by 7.04% to -$76000.0 in 2026.
  • Business Quant data shows Non Operating Income for TLSI at -$76000.0 in Q1 2026, -$71000.0 in Q4 2025, and -$94000.0 in Q3 2025.